Par, an Endo company, is introducing the first generic version of Pfizer's Chantix (varenicline tablets), in dosage strengths of 0.5 mg and 1 mg.
Par's varenicline is the first and currently the only available FDA-approved generic version of Chantix in the United States. It is used to help adults stop smoking.
[Read more: Par launches authorized generic of Amitiza]
"This important approval brings the first Chantix generic to the U.S. market," said Jon Holden, senior vice president and general manager, Generics at Endo. "As a reliable, quality supplier, Par is proud to help people during this critical time while also expanding our product portfolio."
Chantix has a market value of approximately $1 billion for the 12 months ended June 30, according to IQVIA.